Context Therapeutics Inc. (CNTX) Statistics & Valuation Metrics - Stocknear

Context Therapeutics Inc.

NASDAQ: CNTX · Real-Time Price · USD
0.91
0.01 (0.76%)
At close: Sep 26, 2025, 3:59 PM
0.93
2.62%
After-hours: Sep 26, 2025, 06:30 PM EDT

Context Therapeutics Statistics

Share Statistics

Context Therapeutics has 89.7M shares outstanding. The number of shares has increased by 19.61% in one year.

89.7M
19.61%
0%
75.02%
58.82M
234
0.13%

Short Selling Information

The latest short interest is 506.95K, so 0.57% of the outstanding shares have been sold short.

506.95K
0.57%
0.69%
6.94

Valuation Ratios

The PE ratio is -2.3 and the forward PE ratio is -2.16. Context Therapeutics's PEG ratio is 0.03.

-2.3
-2.16
0
40.8
0.64
-2.09
0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Context Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 35.62, with a Debt / Equity ratio of 0.

35.62
35.62
0
-0.01
-0.01
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-2.23M
12
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by -51.08% in the last 52 weeks. The beta is 1.91, so Context Therapeutics's price volatility has been higher than the market average.

1.91
-51.08%
0.83
0.83
55.06
176,076

Income Statement

n/a
n/a
-29.92M
-26.73M
-26.67M
-26.73M
-0.46
Full Income Statement

Balance Sheet

The company has 94.43M in cash and 219.38K in debt, giving a net cash position of 94.21M.

94.43M
219.38K
94.21M
-94.78M
87.15M
82.19M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -14.56M and capital expenditures -14.76M, giving a free cash flow of -29.31M.

-14.56M
-14.76M
-29.31M
-0.5
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

CNTX does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for CNTX is $4, which is 339.6% higher than the current price. The consensus rating is "Buy".

$4
339.6%
Buy
6
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

7.74
2